Increased Serum G Protein-coupled Estrogen Receptor 1 Levels and Its Diagnostic Value in Drug Naïve Patients with Major Depressive Disorder
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The facts that depression is more prevalent in females than in males and females are exposed to depression more commonly during certain hormonal fluctuating periods indicate the role of sex hormones in physiopathology. Estrogen acts over estrogen receptors alpha and beta and recently identified G protein-coupled estrogen receptor 1 (GPER1). The present study aimed, for the first time, to evaluate serum GPER1 levels in drug-naïve major depressive disorder (MDD) patients. Methods: The study included 56 newly diagnosed drug-naïve MDD patients aged between 18 and 50 years and 42 age- and gender-matched healthy volunteers. Medical history was obtained and physical examinations, laboratory tests, and the Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A) were performed. The serum GPER1 levels were measured. Results: The HAM-D score was significantly higher in the MDD patients than in the controls. The GPER1 level was significantly higher in the MDD patients than in the controls. A positive correlation was found with GPER1 levels and depression scores. The receiver operating characteristic analysis revealed sensitivity, specificity, positive predictive value, and negative predictive value as 82.1%, 90.5%, 92.0%, and 79.2%, respectively, for the presence of depression, when the serum GPER1 value was ≥0.16. Conclusion: This study demonstrated significantly higher serum GPER1 levels in the MDD patients than in the controls, a positive correlation was found between GPER1 levels and depression scores and serum GPER1 level was valuable in predicting the presence of depression.
Abstract
Objective: The facts that depression is more prevalent in females than in males and females are exposed to depression more commonly during certain hormonal fluctuating periods indicate the role of sex hormones in physiopathology. Estrogen acts over estrogen receptors alpha and beta and recently identified G protein-coupled estrogen receptor 1 (GPER1). The present study aimed, for the first time, to evaluate serum GPER1 levels in drug-naïve major depressive disorder (MDD) patients. Methods: The study included 56 newly diagnosed drug-naïve MDD patients aged between 18 and 50 years and 42 age- and gender-matched healthy volunteers. Medical history was obtained and physical examinations, laboratory tests, and the Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A) were performed. The serum GPER1 levels were measured. Results: The HAM-D score was significantly higher in the MDD patients than in the controls. The GPER1 level was significantly higher in the MDD patients than in the controls. A positive correlation was found with GPER1 levels and depression scores. The receiver operating characteristic analysis revealed sensitivity, specificity, positive predictive value, and negative predictive value as 82.1%, 90.5%, 92.0%, and 79.2%, respectively, for the presence of depression, when the serum GPER1 value was ≥0.16. Conclusion: This study demonstrated significantly higher serum GPER1 levels in the MDD patients than in the controls, a positive correlation was found between GPER1 levels and depression scores and serum GPER1 level was valuable in predicting the presence of depression.
참고문헌 (49)
- Kessler RC, "The costs of depression", Psychiatr Clin North Am, 35, pp.1~14 (2012)
- ter Horst JP, "Relevance of stress and female sex hormones for emotion and cognition", Cell Mol Neurobiol, 32, pp.725~735 (2012)
- Soares CN, "Depression in peri- and postmenopausal women: prevalence, pathophysiology and pharmacological management", Drugs Aging, 30, pp.677~685 (2013)
- Solomon MB, "Sex differences in psychopathology:of gonads, adrenals and mental illness", Physiol Behav, 97, pp.250~258 (2009)
- Studd J, "Reproductive depression", Gynecol Endocrinol, 28(Suppl 1), pp.42~45 (2012)
- Payne JL, "The role of estrogen in mood disorders in women", Int Rev Psychiatry, 15, pp.280~290 (2003)
- Westberg L, "Sex steroid-related candidate genes in psychiatric disorders", J Psychiatry Neurosci, 33, pp.319~330 (2008)
- Wittmann W, "Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone", Neuropsychopharmacology, 34, pp.775~785 (2009)
- Barton M, "Position paper: The membrane estrogen receptor GPER--Clues and questions", Steroids, 77, pp.935~942 (2012)
- Krezel W, "Increased anxiety and synaptic plasticity in estrogen receptor beta-deficient mice", Proc Natl Acad Sci U S A, 98, pp.12278~12282 (2001)
- 김미진, "G-protein Coupled Estrogen Receptor (GPER", GPR30) and Women’s Health, 2015, pp.21(2), 79~81[DOI]
- Langer G, "A critical review of fundamental controversies in the field of GPR30 research", Steroids, 75, pp.603~610 (2010)
- Dennis MK, "In vivo effects of a GPR30 antagonist", Nat Chem Biol, 5, pp.421~427 (2009)
- Kastenberger I, "Activation of the G-protein-coupled receptor GPR30 induces anxiogenic effects in mice, similar to oestradiol", Psychopharmacology (Berl), 221, pp.527~535 (2012)
- Hiles SA, "A meta-analysis of differences in IL-6 and IL-10 between people with and without depression : exploring the causes of heterogeneity", Brain Behav Immun, 26, pp.1180~1188 (2012)
- Howren MB, "Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis", Psychosom Med, 71, pp.171~186 (2009)
- Ozcan ME, "Antioxidant enzyme activities and oxidative stress in affective disorders", Int Clin Psychopharmacol, 19, pp.89~95 (2004)
- Findikli E, "The biomarker potential of malondialdehyde, superoxide dismutase and catalase activity in drug naïve, first episode, non-smoker generalized anxiety disorder patients", Clin Psychopharmacol Neurosci (2016)
- Han G, "GPER : a novel target for non-genomic estrogen action in the cardiovascular system", Pharmacol Res, 71, pp.53~60 (2013)
- Stygar D, "Identification of wild type and variants of oestrogen receptors in polymorphonuclear and mononuclear leucocytes", Clin Endocrinol(Oxf), 64, pp.74~81 (2006)
- Revankar CM, "A transmembrane intracellular estrogen receptor mediates rapid cell signaling", Science, 307, pp.1625~1630 (2005)
- Sandén C, "G proteincoupled estrogen receptor 1", G protein-coupled receptor 30localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments, 2011, pp.79, 400~410
- Fındıklı E, "Serum levels of G protein-coupled estrogen receptor 1(GPER1)in drug-naive patients with generalized anxiety disorder", Psychiatry Res, 244, pp.312~316 (2016)
- Prossnitz ER, "The G-protein-coupled estrogen receptor GPER in health and disease", Nat Rev Endocrinol, 7, pp.715~726 (2011)
- Phan KL, "Functional neuroanatomy of emotion : a meta-analysis of emotion activation studies in PET and fMRI", Neuroimage, 16, pp.331~348 (2002)
- van Amelsvoort T, "In vivo assessment of the effects of estrogen on human brain", Trends Endocrinol Metab, 12, pp.273~276 (2001)
- Yaffe K, "Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence?", Ann N Y Acad Sci, 949, pp.215~222 (2001)
- Cyr M, "Modulation by estrogenreceptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain", Neuropsychopharmacology, 23, pp.69~78 (2000)
- Matsuda Y, "Effects of estrogen on acetylcholine release in frontal cortex of female rats : involvement of serotonergic neuronal systems", Brain Res, 937, pp.58~65 (2002)
- Mössner R, "Serotonin transporter function is modulated by brain-derived neurotrophic factor(BDNF)but not nerve growth factor(NGF)", Neurochem Int, 36, pp.197~202 (2000)
- Mössner R, "The serotonin transporter in Alzheimer's and Parkinson's disease", J Neural Transm Suppl, (60), pp.345~350 (2000)
- Osterlund MK, "Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A)receptor mRNA and binding levels in the rat brain", Synapse, 35, pp.39~44 (2000)
- Joffe H, "Treatment of depression and menopauserelated symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine", J Clin Psychiatry, 68, pp.943~950 (2007)
- Soares CN, "Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms", J Clin Psychiatry, 64, pp.473~479 (2003)
- Thase ME, "Relative antidepressant efficacy of venlafaxine and SSRIs : sex-age interactions", J Womens Health(Larchmt), 14, pp.609~616 (2005)
- Keyes K, "The role of allelic variation in estrogen receptor genes and major depression in the Nurses Health Study", Soc Psychiatry Psychiatr Epidemiol, 50, pp.1893~1904 (2015)
- Walf AA, "A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior", Neuropsychopharmacology, 31, pp.1097~1111 (2006)
- Prossnitz ER, "physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER", Prostaglandins Other Lipid Mediat, 89, pp.89~97 (2009)
- Hazell GG, "Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues", J Endocrinol, 202, pp.223~236 (2009)
- Prossnitz ER, "Estrogen biology : new insights into GPER function and clinical opportunities", Mol Cell Endocrinol, 389, pp.71~83 (2014)
- Studd JW, "A guide to the treatment of depression in women by estrogens", Climacteric, 14, pp.637~642 (2011)
- Benmansour S, "Comparison of the effects of estradiol and progesterone on serotonergic function", Biol Psychiatry, 71, pp.633~641 (2012)
- McAllister CE, "GPER1stimulation alters posttranslational modification of RGSz1and induces desensitization of 5-HT1A receptor signaling in the rat hypothalamus", Neuroendocrinology, 100, pp.228~239 (2014)
- Karlović D, "Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode", J Psychiatr Res, 47, pp.162~167 (2013)
- Fan HM, "Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients", J Psychiatr Res, 59, pp.45~52 (2014)
- Camkurt MA, "Evaluation of malondialdehyde, superoxide dismutase and catalase activity and their diagnostic value in drug naïve, first episode, non-smoker major depression patients and healthy controls", Psychiatry Res, 238, pp.81~85 (2016)
- Anchan D, "GPR30activation decreases anxiety in the open field test but not in the elevated plus maze test in female mice", Brain Behav, 4, pp.51~59 (2014)
- Hart D, "Activation of the G-protein coupled receptor 30(GPR30)has different effects on anxiety in male and female mice", Steroids, 81, pp.49~56 (2014)
- Kastenberger I, "GPER1(GPR30)knockout mice display reduced anxiety and altered stress response in a sex and paradigm dependent manner", Horm Behav, 66, pp.628~636 (2014)